Pramipexol in Parkinson's disease;Pramipexol bei der Parkinson-krankheit

Nervenarzt

Volumn 73, Issue 8, 2002, Pages 745-750

  Reichmann, H ^a   Brecht, H M ^b   Kraus, P H ^c   Lemke, M R ^d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Depression; Parkinson; Pramipexole; SPES; Tremor

Indexed keywords

LEVODOPA; PRAMIPEXOLE;

AGED; ANHEDONIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE COURSE; DISORIENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EVALUATION; FEMALE; HALLUCINATION; HUMAN; HYPERKINESIA; MAJOR CLINICAL STUDY; MALE; MOOD; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; PSYCHOSIS; RATING SCALE; SELF CONCEPT; SHORT PARKINSON EVALUATION SCALE; SIDE EFFECT; SNAITH HAMILTON PLEASURE SCALE; TREMOR; TREMOR IMPACT SCALE;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CLINICAL TRIALS; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, DOPAMINE D2; THIAZOLES; TREATMENT OUTCOME;

EID: 0036938278     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-002-1318-z     Document Type: Article

References (25)

1. Clarke CE, Speller JM, Clarke JA (2000) Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev CD002261
2. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11: 58-65
3. Franz M, Lemke MR, Meyer T, Ulferts J, Puhl P, Snaith RP (1998) Deutsche Version der Snaith-Hamilton-Pleasure-Scale (SHAPS-D): Erfassung von Anhedonie bei schizophrenen und depressiven Patienten. Fortschr Neurol Psychiat 66: 407-413
4. Goldberg JF, Frye MA, Dunn RT (1999) Pramipexole in refractory bipolar depression. Am J Psychiatry 156 (5): 798
5. Guttman M, Jaskolka J (2001) The use of pramipexole in Parkinson's disease: Are its actions D3 mediated? Parkinsonism Relat Disord 7: 231-234
6. Hoehn M, Yahr M (1967) Parkinsonism: Onset, progression and mortality. Neurology 17: 427-442
7. Kieburtz, K. and the Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose ranging study. JAMA 278: 125-130
8. Kuenig G, Pogarell O, Moller JC, Delf M, Oertel WH (1999) Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol 22: 301-305
9. Lieberman A, Minagar A, Pinter MM (2000) The effect of pramipexole in the treatment of Parkinson's disease. Rev Contemp Pharmacother 12: 59-86
10. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K (1997) Antidepressant effects of pramipexole a novel dopamine receptor agonist. J Neural Transm 104 (4/5): 525-533
11. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3,and D4 receptors. Eur J Pharmacol Mol Pharmacol Sect 290 (1): 29-36
12. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58: 11-17
13. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines. Neurology 56 [Suppl 5]: S1-S88
14. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson's disease. JAMA 284: 1931-1938
15. Parkinson Study Group (2002) Pramipexole versus Levodopa Initial Treatment for Parkinson Disease: A 4-year Randomized Controlled Trial. 54th Annual Meeting of the American Academy of Neurology, April, Denver
16. Parkinson Study Group (2002) Pramipexole versus Levodopa effects on Parkinson disease progression assessed by dopamine transporter brain imaging. JAMA (in press)
17. Rabey JM, Bass H, Bonucelli U et al. (1997) Evaluation of the short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 20: 322-337
18. Rektorova I, Rektor I, Bares M et al. (2001) Depression in Parkinson's disease: an eightmonth, randomised, open-label, national multi-centre comparative study of pramipexole and pergolide. Mov Disord 16 [Suppl 1]: 32
19. Schneider CS, Mierau J (1987) Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. J Med Chem 30, 494-498
20. Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49: 724-728
21. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P (1995) A scale for the assessment of hedonic tone. The Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167: 99-103
22. Sporn J, Ghaemi SN, Sambur MR et al. (2000) Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 12 (3): 137-140
23. Szegedi A, Hillert A, Wetzel H, Klieser E, Gaebel W, Benkert O (1997) Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 20 [Suppl 1]: 36-45
24. van Hilton JJ, van de Beek WJT (in Vorbereitung) The tremor impact scale (TIS): a short evaluation of tremor-related physical and psychosocial disability.
25. Willner P, Lappas S, Cheeta S, Muscat R (1994) Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology 115 (4): 454-462